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The crucial roles of oxidative stress and inflammation in the development of hepatic diseases have been unraveled and emphasized
for decades. From steatosis to fibrosis, cirrhosis and liver cancer, hepatic oxidative stress, and inflammation are sustained and
participated in this pathological progressive process. Notably, increasing evidences showed that oxidative stress and inflammation
are tightly related, which are regarded as essential partners that present simultaneously and interact with each other in various
pathological conditions, creating a vicious cycle to aggravate the hepatic diseases. Clarifying the interaction of oxidative stress and
inflammation is of great importance to provide new directions and targets for developing therapeutic intervention. Herein, this
review is concerned with the regulation and interdependence of oxidative stress and inflammation in a variety of liver diseases.
In addition to classical mediators and signaling, particular emphasis is placed upon immune suppression, a potential linkage of
oxidative stress and inflammation, to provide new inspiration for the treatment of liver diseases. Furthermore, since antioxidation
and anti-inflammation have been extensively attempted as the strategies for treatment of liver diseases, the application of herbal
medicines and their derived compounds that protect liver from injury via regulating oxidative stress and inflammation collectively
were reviewed and discussed.
1. Introduction
Liver disease, a broad spectrum of disease ranging from early
steatosis to severe hepatitis, fibrosis, cirrhosis, and hepato-
cellular carcinoma (HCC), has high prevalence worldwide.
Hepatic diseases could be triggered by various risk factors
including obesity, virus, alcohol, drugs, and other toxins [1].
As liver is a central organ detoxification and nutrients me-
tabolism, it is more vulnerable to oxidative stress and in-
flammation produced from toxins and metabolites in the
body [2]. A huge number of animals studies and clinical tri-
als have demonstrated that sustained oxidative stress and
inflammation in the liver are crucial in the initiation and
development of hepatic illness, regardless of the etiology [3].
Both of them are considered to be the key elements in the
pathogenesis of acute and chronic liver diseases. Oxidative
stress causes hepatic damage by provoking alteration of
biological molecules such as DNA, proteins, and lipids and,
notably, modulating biological pathways associated with
genes transcription, protein expression, cell apoptosis, and
hepatic stellate cell activation [2]. Regarding inflammation,
it is an essential component of the immune response and
manifested as infiltration of inflammatory cells to primarily
liver for fighting against pathogens invasion; however, once
the stimuli exist persistently or overwhelmingly, they in turn
lead to cellular injury and lipid accumulation associated with
increased risk of severe liver diseases such as steatohepatitis,
fibrosis, and cancer [4–6].
Of great interest, investigations focusing on the relation-
ship and interaction of oxidative stress and inflammation
have attracted great attention as accumulated evidences indi-
cated that they are tightly correlated and orchestrated to drive
the pathophysiological procedure of liver diseases [7–9]. At
the early stage of liver diseases, either of them may solely
present, but both should participate in the pathogenesis of
various liver diseases together at later stages. Besides, a num-
ber of reactive oxygen species (ROS) or reactive nitrogen
species (RNS) can augment proinflammatory gene expression
by provoking intracellular signaling cascade. On the other
hand, inflammatory cells could produce more ROS/RNS,
resulting in exaggerated oxidative stress at inflammatory
lesion [7, 10]. The close interplay of oxidative stress and
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inflammation thus creates a vicious cycle that promotes
the pathogenesis of liver diseases. In general, antioxidative
therapy showed unsatisfied outcomes in many clinical trials,
though numerous studies demonstrated actual involvement
of oxidative stress in the pathogenesis in the disease. This
has been called as the phenomenon of antioxidant paradox
in medical science [11, 12]. Some researchers proposed that
it is the complex and tight related interdependence between
oxidative stress and inflammation that are responsible for the
failure of antioxidant treatment [7]. For example, antioxidant
that only improves oxidative stress pathways but aggravates
inflammatory cascades is more likely to get failure in treating
liver diseases. Therefore, clarifying the interaction of oxida-
tive stress and inflammation is of great importance for the
selection of antioxidants that block oxidative and inflamma-
tory pathways simultaneously. In this review, we will briefly
summarize the roles of oxidative stress and inflammation
in highly prevalent liver diseases. Then, emphasis will be
put upon the discussion on the relationship and interdepen-
dence of oxidative stress and inflammation in liver diseases
including alcoholic liver disease (ALD), nonalcoholic fatty
liver disease (NAFLD), fibrosis, and HCC.More importantly,
as anti-inflammatory immune suppressor cells also show
linkage with oxidative stress [13], based on data as far now,
potential mechanism by which immune suppression medi-
ated by oxidative stress regulating inflammation is proposed
herein might offer new inspiration for the treatment of liver
disease. Furthermore, many herbal medicines have displayed
antioxidant and anti-inflammatory activity for treatment of
liver diseases by a vast body of studies [8]. Herbal medicines
or purified compounds such as berberine (BBR), curcumin,
lipoic acid (LA), and epigallocatechin gallate (EGCG) which
protect liver from injury via regulating oxidative stress and
inflammation collectively will be briefly summarized and
discussed in this review.
2. Oxidative Stress and Inflammation in
Hepatic Lesion
2.1. Targets and Participation of Oxidative Stress in Liver
Diseases. Oxidative stress is defined as the imbalance be-
tween productions of ROS/RNS generated in the aerobic
metabolism and their elimination by antioxidant defense
including enzymes such as superoxide dismutases (SOD),
catalase (CAT), and glutathione peroxidase (GSH-Px) and
nonenzymes particles of electron receptors such as glu-
tathione (GSH) and vitamin C/E, which could be triggered
in the liver by diverse factors such as obesity, virus, drugs,
alcohol, and other toxins [2]. Under sustained exposure to
the above factors, ROS/RNS are generated overwhelmingly,
thus leading to substantial damage to cell structure and
functions. Targets of these reactive species that cause cellular
and tissue injury include lipids, DNA, proteins, and related
signaling pathways. Free radicals react with lipids to pro-
duce hydroperoxides and endoperoxides, which may suffer
fragmentation to generate reactive intermediates, such as
malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE),
to cause irretrievably covalent adducts with proteins, DNA,
and phospholipids, resulting in cell death [14]. Reactive stress
induced DNA damage primarily occurs in the mitochondrial
genome because (i) mitochondrion is open and circular
without histone protection and (ii) close to reactive species
that is generated heavily inside mitochondrion compared
to nuclear region [15]. Cysteine with the thiol group is a
reactive amino acid of proteins in cells, and the formation of
disulfide by oxidizing two thiols can result in the alteration
of protein function. By targeting thiols of proteins, ROS
can alter signaling pathways such as cellular kinases, phos-
phatases, and transcription factors, which have insightful
impacts in cell proliferation, differentiation, and apopto-
sis leading to hepatocytes injury by stimulating oxidant-
induced hepatocyte apoptosis or by restraining cell survival
signaling cascades [14]. Cellular kinases, particularly in the
mitogen-activated protein kinase (MAPK) family such as
extracellular signal-regulated kinase 1/2 (ERK1/2), c-Jun N-
terminal kinase (JNK), and p38 MAPK, have a critical role
in transducing a multitude of extracellular stimuli by phos-
phorylating and activating downstream transcription factors.
Modulation of protein expression in response to oxidative
stress occurs mainly via the activation of redox-sensitive
transcription factors such as nuclear factor 𝜅B (NF-𝜅B),
activator protein-1 (AP-1), early growth response protein 1
(EGR-1), and G proteins [15, 16]. It is worth noting that the
fate of hepatocytes mainly depends on intensity and duration
of the stimuli, which determines the degree and duration of
the activation/inactivation of these redox-sensitive cascades,
especially the relative level of activation of NF-𝜅B, ERK1/2,
and JNK.
Involvement of oxidative stress in liver diseases has been
extensively explored and its crucial impact on the patho-
genesis of a variety of liver diseases such as ALD, NAFLD,
fibrosis, and HCC has been revealed. In ALD, during the
metabolism process of alcohol in the liver, reactive interme-
diate acetaldehyde, which can react with DNA and proteins
to form adducts, causes tissue injury. Activated cytochrome
P450 2E1 (CYP2E1) responsible for alcohol breakdown in
the case of chronic alcohol exposure commits the gener-
ation of ROS, resulting in fatty acids deposition and the
progress of hepatic steatosis [17, 18]. Additionally, defense
system to remove reactive species is also altered by alcohol,
such as peroxisome proliferator activated receptor gamma-
(PPAR-𝛾-) coactivator 1 𝛼, which can induce activation of
various ROS-mediated detoxifying enzymes [19–22]. ROS
may lead to excessive alcoholic liver fibrosis and cirrhosis
via rebuilding of stellate cells and the extracellular matrix
within the liver. With regard to NAFLD, substantial hepatic
ROS is produced by excessive angiotensin II and activated
CYP2E1, ultimately leading to impaired beta-oxidation and
fatty liver [23]. Fibrosis, a wound-healing response to hep-
atocytes injury, is caused by the overproduction of collagen
I. The elevated oxidative stress contributes to fibrogenesis
via provoking generation of collagen from activated hepatic
stellate cells and release of other profibrogenic cytokines,
growth factors, and prostaglandins [24–26]. Concerning liver
cancer, ROS generated by hypoxia along the edge of tumor
growth presents a dual role: (i) it promotes carcinogenesis by
activatingNF-𝜅B andHIF1𝛼, which favor cancer cell survival,
angiogenesis, and tumor expansion; (ii) on the other hand,
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after mitochondrial GSH depletion, it shifts hypoxia from a
cancer-promoting to a cancer-killing environment [27–29]. It
is proposed that the role of oxidative stress in cancer depends
on the time course: destructive role in the early phase of
carcinogenesis and protective role in late phase.
2.2. Participation of Inflammation in Liver Diseases Spectrum.
When the liver is challenged by exogenous and endogenous
stimuli like virus, allergens, toxins, or obesity, inflammation
usually occurs to protect the liver from injury with character-
istic of leukocytes infiltration such as neutrophils,monocytes,
and lymphocytes. However, once this process is excessive,
prolonged, or dysregulated, pathological inflammation and
tissue injury will occur, which is critical for the initiation
and development of hepatitis, fibrosis, cirrhosis, and liver
cancer [30–32]. Hepatic inflammation has dual roles in the
liver; they are essential to maintain tissue healthy and act
as critical drivers of the liver pathology when persisted or
out of control. The infiltration of leukocytes is a complicated
process involving participation of many receptors, adhesion
molecules, and chemokines, such as selectins, intercellu-
lar adhesion molecule-1 (ICAM-1), vascular cell adhesion
molecule-1 (VCAM-1), and corresponding leukocyte recep-
tors and monocyte chemoattractant protein 1 (MCP-1). In
addition to hepatocyte death-mediated leukocytes infiltra-
tion, infiltrated inflammatory cells also produce soluble
mediators, such asmetabolites of arachidonic acid, cytokines,
and chemokines, which activate related signal transduction
cascades and change transcription factors, to further recruit
inflammatory cells to the injured site. Then, liver injury is
deteriorated because of increased cytokines and ligands [6,
33].
Similar to oxidative stress, inflammation is generally
sustained and participated in the whole spectrum of liver
diseases from initial to advanced stage, which is known as
inflammation-fibrosis-cancer axis [8]. With the progression
to chronic liver diseases, both innate and adaptive immune
response are triggered by leukocytes infiltration, activation
of Kupffer cells (KCs), and upregulation of inducible nitric
oxide synthase (iNOS) [34]. Leukocytes and KCs produce
huge amounts of nitric oxide and cytokines, such as potent
profibrogenic cytokine, TGF-𝛽4, and inflammation modu-
lator, TNF-𝛼. Plentiful inflammatory mediators including
inflammatory cytokines, chemokines, and Toll-like receptors
(TLRs) are involved in the regulation of hepatic fibrogenesis
[34–36]. Particularly, TLRs, a family of pattern recognition
receptors serving as important innate immune response fac-
tors, play a vital role in the pathogenesis of liver disease [37].
As Toll-like receptors are redox-sensitive receptor proteins
and have been involved in cellular response to oxidative
stress, the effect of lipid peroxidation caused by oxidants on
TLRs is worth to be explored in the future. As amatter of fact,
NF-𝜅B and JNKs are considered as the most key signaling
pathways linking inflammation and fibrosis. Hyperactivation
of NF-𝜅B in hepatocytes or infiltrated inflammatory cells
fosters hepatic inflammation by increased generation of
proinflammatory cytokines, such as IL-1𝛽, TNF-𝛼, and IL-
6 [16]. Mediators like IL-1𝛽 and TNF-𝛼 could activate NF-
𝜅B in hepatic stellate cells (HSCs) and promote survival
of HSCs and fibrogenesis. Recently, it was discovered that
ubiquitin-editing protein A20, an important regulator of
inflammatory signaling to block NF-𝜅B activation, prevents
the development of chronic hepatic inflammation and cancer
by protecting hepatocytes from death [38]. JNK is involved
in multiple signaling cascades related with hepatocellular
injury, as well as regulating hepatic steatosis and inflam-
matory gene expression. It has direct profibrogenic role by
stimulating platelet-derived growth factor (PDGF), TGF-𝛽,
and angiotensin II-induced proliferation, 𝛼-smooth muscle
actin (𝛼-SMA) expression, and collagen production [6, 39,
40]. Moreover, inflammation is intensively implicated in car-
cinogenesis of HCC [41]. Chronic inflammation is involved
in the process of cellular transformation, promotion, prolif-
eration, invasion, angiogenesis, andmetastasis of carcinogen-
esis [42]. The generation of proinflammatory cytokines like
cyclooxygenase-1 (COX-1), COX-2, TNF-𝛼, IL-1, IL-26, IL-8,
IL-18, and macrophage inflammation protein-1 (MIP-1𝛼) via
activation of NF-𝜅B alters the hepatic microenvironment and
leads to fibrosis and carcinogenesis [24, 42].
3. The Relationship and Interdependence
between Oxidative Stress and Inflammation
in Various Liver Diseases
Extensive research has revealed that oxidative stress and
inflammation are tightly interrelated in many diseases, as
displayed in Figure 1. They seem to occur simultaneously
and further promote each other in injury site. On one hand,
continued oxidative stress can lead to chronic inflammation.
Many transcription factors and receptors such as NF-𝜅B,
activator protein-1 (AP-1), p53, hypoxia-inducible factor 1-
alpha (HIF-1𝛼), PPAR-𝛾, 𝛽-catenin/Wnt, and erythroid 2-
related factor 2 (Nrf2) are activated by oxidative stress, which
could regulate the expression of many genes, including those
inflammatory cytokines and anti-inflammatory molecules
[43]. For example, a pattern recognition receptor, NOD-
like receptor protein 3 (NLRP3) that triggers innate immune
response through promotingmaturation of proinflammatory
cytokines like IL-1𝛽 and IL-18, can be activated by oxidative
stress and thus leads to inflammation [7, 43, 44]. Of note,
NF-𝜅B signaling plays a key role in oxidative stress-mediated
inflammation response [16]. Apart from the direct activation
of NF-𝜅B via oxidative stress, damaged DNA induced by
ROS also results in inflammation through NF-𝜅B pathway
[16]. Recently, it was found that the release of oxidized
peroxiredoxin-2 (PRDX2) and substrate thioredoxin from
macrophages could alter the redox status of cell surface
receptors and induce inflammation via TNF-𝛼 production
in an oxidative cascade [45], which provides a new linkage
of inflammation and oxidative stress. On the other hand,
sustained inflammation could induce oxidative stress. Infil-
trated immune cells and activated phagocytic cells such as
neutrophils and macrophages produce large amounts of ROS
and RNS like superoxide, hydrogen peroxide, hydroxyl free
radical, peroxynitrite, and nitric oxide.These reactive species,
which are generated to invade agents, can induce localized
oxidative stress when diffused out of the phagocytic cells
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Figure 1: Potential interaction of oxidative stress and inflammation.
[44, 46]. In addition to direct production of ROS/RNS by
phagocytic cells, in response to proinflammatory cytokines
such as IL-6 and interferon-gamma (IFN-𝛾), the nonphago-
cytic cells can also produce reactive species. Redox-sensitive
signal transduction pathways such as JNK and p38 MAPK
also play vital roles in the interaction between inflammation
and oxidative stress [14].
3.1. Alcoholic Liver Disease. As mentioned before, both gen-
eration of ROS/RNS and activation of inflammation are
critical for hepatic damage induced by alcohol. The oxida-
tive microenvironment created by ROS/RNS via alcohol
metabolism process activates stress-related proteins, facili-
tates adduct formation, and induces endoplasmic reticulum
stress, resulting in hepatocellular damage [47]. Particularly,
the contributions of oxidative stress in promoting adaptive
immune responses in alcoholic liver disease (ALD) have
been reported [21, 48]. Oxidative stress has been considered
as a trigger for adaptive immune responses in patients of
alcoholic liver disease. The adaptive immune responses to
MDA adducts indicates that oxidative stress may represent
an important stimulus for the development of immune
responses associatedwith advancedALD [21].The infiltration
of inflammatory cells, activation of macrophage, and the
proinflammatory mediators like LPS, TNF-𝛼, IL1𝛽, and IL6
induced by various pathways, such as alcohol-regulated
CD14/Toll-like receptor 4 (TLR4) pathway, could provoke
cellular injury and apoptosis, resulting in ALD [18, 19]. The
activation of KCs by lipopolysaccharides (LPS) via TLR4
is critical to the onset of alcohol-induced hepatic dam-
age, which could enhance the production of inflammatory
cytokines and ROS which contribute to ALD [31, 49, 50].
MicroRNA-155, an important regulator of inflammation, has
been demonstrated to play a vital role in alcohol-induced
steatohepatitis and fibrosis. It was found that miR-155 knock-
out mice are protected from alcohol-induced steatosis and
inflammation, which might be attributed to increased per-
oxisome proliferator-activated receptor response element
(PPRE) and PPAR-𝛼 binding and decreased MCP1 produc-
tion [51]. In the past, the role of oxidative stress and inflam-
mation in the pathophysiological process of ALD was inves-
tigated individually. However, of note, with better under-
standing of this disease, recent studies have begun to explore
the interconnected relationship between oxidative stress and
inflammation [10].
Several signaling pathways have been identified to be
involved in oxidative stress-mediated aggravated inflamma-
tion in ALD as shown in Figure 2. The I𝜅B kinase (IKK)
kinase activation that leads to the production of proinflam-
matory cytokines could be accentuated by oxidative stress
in ALD, for example, ROS-mediated molecular chaperones
such as Hsp90 [31, 52–54]. Notch1 and NF-𝜅B that have
been intensively implicated in inflammatory diseases were
found to be important mediators in oxidative stress-induced
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Figure 2: Several signaling pathways involved in oxidative stress-mediated aggravated inflammation in ALD.
alcoholic steatohepatitis [55]. NADPH oxidase, a source of
ROS in ALD, can increase NF-𝜅B activation and phosphory-
late ERK1/2 and p38 MAPK kinases that intensify the pro-
duction of TNF-𝛼 from KCs [53]. In previous study, the
role of alcohol-induced oxidative stress in modulating proin-
flammatory cytokines production in alcoholic steatohepatitis
was determined. It was found that LPS improved TNF-𝛼,
macrophage inflammatory protein-alpha (MIP-1𝛼), MCP-1,
and cytokine-induced neutrophil chemoattractant 1 (CINC-
1) in KCs-SV40, whereas TNF-𝛼 upregulated CINC-1, IFN-
𝛾-inducible protein 10 (IP-10), and MIP-2 expression in
H4IIEC3 hepatoma cells in a dose-dependent matter. When
stimulated by combination of hydrogen peroxide with LPS
or TNF-𝛼, KCs-SV40 and hepatocytes increased production
of proinflammatory cytokines through NF-𝜅B activation
and histone H3 hyperacetylation. But regarding LPS-treated
KCs-SV40, 4-hydroxynonenal showed inhibitory effect on
cytokine production via significantly enhancing mRNA
degradation of cytokines like TNF-𝛼, MIP-1𝛼, and MCP-
1 and decreased the MCP-1 protein level by diminishing
the phosphorylation of mRNA binding proteins [56]. This
study indicates that the role of oxidative stress in regu-
lating inflammatory cytokine production is dependent on
cell type, while NF-𝜅B signaling, histone acetylation, and
mRNA stability are implicated in this regulation process [56].
Interferon regulatory factor 3 (IRF3) and signal transducer
and activator of transcription 3 (STAT3) have also been
proposed to increase hepatic proinflammatory cytokines in
ALD in association with oxidative stress, which needs further
study to confirm.These signaling pathways are of great value
to be specifically targeted for ALD treatment.
3.2. Nonalcoholic Fatty Liver Disease. Nonalcoholic fatty liver
disease (NAFLD), which is characterized by excessive lipid
accumulation in the liver, is similar to ALD thatmay progress
from simple steatosis to steatohepatitis, fibrosis, cirrhosis, or
evenHCC [57, 58]. However, unlikeALDwhich is induced by
heavy alcoholic consumption, the major etiology of NAFLD
is obesity, insulin resistance (IR), dyslipidemia, or diabetes
[52, 59]. Due to high caloric diet and life style, NAFLD has
an increasing prevalence in Western society and even in
the world. In the regard of pathogenesis of NAFLD, two hit
hypotheses are widely proposed. It is believed that steatosis
resulted from accumulated triglycerides and free fatty acid in
the liver because of obesity or insulin resistance is the first hit,
which might be a benign and stable pathology [60, 61]. There
exist other pathological “hits” including oxidative stress and
hepatic inflammation which may promote simple steatosis to
further complications like fibrosis or cirrhosis [31].Therefore,
the importance of oxidative stress and inflammation in the
pathogenesis of NAFLD is beyond doubt.
In nonalcoholic steatohepatitis (NASH), ROS are gener-
ated via a variety of ways [62]. 𝛽-Oxidation of overload fatty
acid is regarded as the major source of reducing equivalents
responsible for increased ROS production. Also, TNF-𝛼
and lipid peroxidation products, which inhibit the electron-
transport chain of themitochondria, could inducemitochon-
drial dysfunction and increase the production of ROS [63].
Mitochondrial damage will result in secondary inhibition of
lipids 𝛽-oxidation and further increase the level of steatosis.
In the cytosol, xanthine oxidase, a key enzyme for the
degradation of purine, catalyzes the reaction of hypoxanthine
to uric acid in which large amounts of superoxide anions
are generated. Increased xanthine oxidase activity induced
by 4-HNE may cause further hepatic damage via ROS
[64]. The microsomal cytochromes CYP2E1 and CYP4A are
involved in the lipooxygenation of long chain fatty acids with
generation of ROS [65]. Moreover, CYP2E1 can be upregu-
lated by free fatty acids as well as insulin resistance, which
could enhanceNADPHoxidase enzyme, leading to increased
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Figure 3: Potential interactions between oxidative stress and inflammation in the context of NAFLD.
production of superoxide [66, 67]. In terms of inflammation,
infiltration of various inflammatory cells like neutrophils,
macrophages, T helper cells, natural killer T (NKT) cells,
and natural killer (NK) cells and upregulation of inflam-
matory mediators such as TNF-𝛼, IL-6, and IL-1𝛽 occur
in steatohepatitis, which contributes to insulin resistance as
well as other metabolic dysregulations, and play a key role
in promoting the progression of steatohepatitis to fibrosis,
cirrhosis, and cancer [32]. For example, lipid peroxidation-
activated KCs could induce production of TNF-𝛼. In the
initial phase of NAFLD, resident immune cells such as KCs
and dendritic cells respond to early signs of hepatocellular
damage by generating plentiful proinflammatory cytokines
like IL-1𝛽 and chemokines like chemokine ligand 2 (CCL2),
which further promote inflammatory cell infiltration, thus
leading to a vicious cycle [64, 68]. It was reported recently
that early depletion of KCs using liposomal clodronate could
block the development of NASH [69]. In addition, several
mediators have been demonstrated which play a positive
role in regulating inflammation in the context of NAFLD.
For example, IL-15 upregulates expression of chemokines
like CCL2, CCL5, and CXCL10 and increases infiltration of
mononuclear cells, promoting inflammation in NAFLD [70].
Tumor necrosis factor receptor-associated factor 1 (TRAF1),
an important adapter protein, is extensively implicated in
mediating immunity/inflammation and cell death. It was
reported recently that TRAF1 functions as a positive regulator
of inflammation and hepatic steatosis in NAFLD through the
activation of ASK1-P38/JNK axis [71]. Moreover, component
C5, a central mediator of inflammation, was also found to
contribute to liver steatosis and inflammation inNAFLD [72].
Accumulating evidences showed tight interaction be-
tween oxidative stress and inflammation in the context of
NAFLD (Figure 3). Firstly, ROS can induce lipid peroxidation
process in which HNE and MDA are generated, which can
freely diffuse into the extracellular space to affect nucleotide
and protein synthesis and thereby increase proinflammatory
cytokine and activate hepatic stellate cells, ultimately leading
to inflammation and the progression of NASH [73, 74]. It
was found that the levels of markers of lipid peroxidation and
oxidative DNA damage, such as HNE and 8-hydroxydeoxy-
guanosine, are correlatedwith the severity of necroinflamma-
tion and fibrosis in patients with NAFLD [61, 75]. Lipid per-
oxidation products developed from phospholipids oxidation
can induce adaptive immune responses by forming immuno-
genic adducts through the interaction with cellular proteins.
High titres of antibodies against lipid peroxidation-derived
antigens are associated with increased hepatic inflammation
and advanced fibrosis in patients with NAFLD [76, 77].
Specifically, ROS and lipid peroxidation induce inflammation
through promoting the release of proinflammatory cytokines,
resulting in neutrophil chemotaxis and lesions of NASH [23].
For example, ROS activate NF-𝜅B signaling pathway, leading
to the synthesis of TNF-𝛼 and the upregulated TGF-𝛽, IL-8,
IL-6, and Fas ligand. Recently, Satapati et al. reported that the
induction of biosynthesis via hepatic anaplerotic/cataplerotic
pathways is amplified by increased oxidative metabolism
and further contributes to oxidative stress and inflammation
during NAFLD [78]. Furthermore, TGF-𝛽, IL-8, and HNE
are chemoattractants of human neutrophils, which may
result in more neutrophil infiltration. On the other hand,
infiltrated neutrophils and other immune cells produce more
ROS in hepatic lesion. Moreover, increased proinflammatory
mediators such as TNF-𝛼 also cause the increase of ROS,
leading to mitochondrial dysfunction [74, 79, 80].
3.3. Liver Fibrosis. Liver fibrosis, a reversible multicellular
wound healing process that results from chronic liver injuries
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with excessive collagen and extracellular matrix (ECM), is
characterized by perpetuation of parenchymal necrosis, infil-
tration of inflammatory cells, and activation of HSCs, ma-
crophages, and KCs, regardless of the etiology [25, 81, 82].
Various growth factors, inflammatory cytokines and che-
mokines, accumulated ECM, and oxidative stress have been
proposed to play a role in fibrogenesis.
Oxidative stress-related molecules and pathways can
modulate tissue and cellular events involved in the patho-
genesis of liver fibrosis [24]. The presence of oxidative stress
and decreased antioxidant defenses caused by stimulus has
been detected in almost all settings of fibrosis and cirrhosis in
clinical and animal model. The disruption of lipids, proteins,
and DNA caused by oxidative stress will induce necrosis and
hepatocytes death and intensify the inflammatory response,
resulting in the initiation of fibrosis [83]. Those ROS can
stimulate the production of profibrogenic mediators from
infiltrated inflammatory cells. Remarkably, ROS can interact
directly with HSCs, which are the main executors of fibroge-
nesis to generate ECM.The cellular redox environment could
regulate the entry of quiescent HSCs into activated cycle
[24, 84]. Redox-sensitive transcription factors such as NF-𝜅B
are important to regulate the activities of antioxidant enzymes
that mediate ROS signaling. Compared with activated HSCs,
the expression of NF-𝜅B in quiescent HSCs is lacking, imply-
ing that a redox-sensitive activation of NF-𝜅B can regulate
expression of related genes, delivering a proper cellular redox
microenvironment for quiescent HSCs into the proliferative
cycle [24, 35, 85]. Phagocytosis of apoptotic bodies by HSCs
inducesNADPHwith production of oxidative radicals, which
is implicated in liver fibrosis in vivo [86]. Furthermore, ROS
can also interact with HSCs to activate fibrosis by DNA
methylation, histone modifications, and gene silencing by
noncoding RNA species. The adaptive immune response
induced by oxidative stress like lipid peroxidation products
likeMDAand 4-HNEwas also implicated in the development
from fatty liver to fibrosis. It was suggested that the adaptive
immune reactions triggered by oxidative stress could be an
independent predictor of progression of NAFLD to advanced
fibrosis [76].
In the initial phase of hepatic injury, inflammation trig-
gered by initial cell death contributes to the removal of cellu-
lar debris and promotes liver regeneration, ensuring restora-
tion of hepatic architecture and function after acute liver
injury [87, 88]. However, once underlying disease cannot be
eliminated and the stimuli sustains, chronic inflammation
and progressive liver fibrosis will be induced [40]. As amatter
of fact, cell death and persisted overwhelming inflammation
are the characteristics of chronic liver diseases that progress
to fibrosis. A variety of inflammatorymediators and pathways
could regulate the activation of HSCs and their survival
after activation [89]. It has been found that inflammatory
cytokines like IL-1𝛽, TNF-𝛼, and IL-17/20/33, chemokines
like MCP-1 and CXCL10, and TLR pathway are intensively
involved in the regulation of hepatic fibrogenesis [90–93]. T
cells response also plays a vital role in regulating the progres-
sion of fatty liver to advanced-stage liver disease [94–96]. It
has been indicated that hepatic recruitment of T helper cells
and cytotoxic T cells contributes to hepatic inflammation,
leading to the development from simple fatty liver to steato-
hepatitis [97]. T helper cells and cytotoxic T cells infiltration
was correlated with the progression of NASH, paralleling the
worsening of parenchymal injury and lobular inflammation
[96]. CD4+T helper cells may promote hepatic inflammation
through upregulation of IFN-𝛾 and CD40 ligand [98]. But
the underlying mechanism of CD8+ cytotoxic T cells in
promoting NASH progression is still unclear.
Thus, oxidative stress and inflammation interact with
each other in multiple ways, thereby creating a favorable
microenvironment for fibrogenesis (Figure 4). In addition to
direct interplay of ROS and inflammation, the activatedHSCs
are a vital bridge to link them together. Both oxidative stress
and inflammatory mediators play a role in the activation
of HSCs, and, conversely, activated HSCs could in turn
enhance cellular oxidative stress and inflammation. On one
hand, redox-sensitive pathways influenced by oxidative stress
regulate the status of HSCs in the initiation phase and
stimulate inflammatory signaling via cytokines, chemokines,
and TLR ligands [25, 99]. On the other hand, HSCs activated
by inflammatory mediators could also inhibit antioxidant
defense and increase the generation of ROS. They work
tightly to form a vicious cycle in the process of liver fibrosis.
Although there are no highly effective antifibrogenic agents
currently available, the potential candidates that can reduce
inflammation and oxidative stress as well as ECM are consid-
ered to be promising for the prevention and treatment of liver
fibrosis. Combination therapy that blocks HSCs activation
via antioxidant and anti-inflammatory pathways would be
effective to inhibit the progression of the pathogenesis of liver
fibrosis.
3.4. Liver Cancer. The initiation and progression of many
cancers have been linked to oxidative stress and inflamma-
tion, as demonstrated by the excessive sustained ROS and
inflammatory mediators. Primary liver cancer, the fifth most
commonmalignancyworldwide, has no exception. Sustained
inflammation is associated with persistent hepatic injury
and concurrent regeneration, leading to sequential develop-
ment of advanced stage of liver disease including fibrosis,
cirrhosis, and eventually HCC [100]. The perpetuation of a
wound-healing response activated by hepatocytes death and
the following inflammatory cascade response is a common
denominator for HCC initiation. Chronic inflammation has
been linked to multiple steps involved in carcinogenesis,
such as cellular transformation, promotion, invasion, angio-
genesis, and metastasis [100, 101]. For example, in context
of hepatic steatosis induced by obesity or other factors,
excessive free fatty acids increase proinflammatory cytokines
and adipokines that can further promote release of TNF-
𝛼 and IL-6 from KCs, leading to activation of downstream
signaling molecules like STAT3 in hepatocytes, which might
result in hepatocarcinogenesis [102–105]. Meanwhile, ROS
are produced over a long time under a sustained environ-
mental stress and contribute to cellular structure damage and
induce DNA damage and mutations in protooncogenes and
tumor-suppressor genes, leading to neoplastic transforma-
tion. Under hypoxic conditions, excessive RNS are generated
through the mitochondrial respiratory chain. The role of
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Figure 4: Oxidative stress and inflammation interact with each other in multiple ways to promote fibrogenesis.
oxidative stress in modulating inflammation-induced car-
cinogenesis in different stage has been systemically reviewed
by Reuter et al. Briefly, under an inflammatory stimulus,
progression of carcinogenesismediated by ROSmay be direct
through oxidation or nitration of DNA or mediated by
the cross-talk signaling pathways related to oxidative stress
and inflammation. The sustained inflammatory/oxidative
microenvironment forms a vicious circle, which can damage
healthy cells like neighboring epithelial and stromal cells,
ultimately resulting in carcinogenesis.
Of note, the participation of ROS in carcinogenesis is
complicated. ROS are regarded as tumorigenic due to their
ability to increase cell proliferation, survival, and cellular
migration as well as gene mutations. However, ROS can also
function as antitumorigenic agents via induction of cellular
senescence and cell death. Whether ROS promote tumor cell
survival or induce cancer cell death remains as a complex
issue, which majorly depends on the location of ROS pro-
duction, the concentration of ROS, and many other factors
such as carcinogenesis stage [15, 29]. For example, cytoglobin
(Cygb), expressed in HSCs, plays a protective role in con-
trolling ROS/RNS in the inflamed liver. Deficiency of Cygb
promoted HCC development in CDAA-fed 𝐶𝑦𝑔𝑏−/− mouse
via upregulating prooxidative genes and downregulating
antioxidative genes [28]. However, ROS produced by NOX2
could inhibit proliferation of cancer stem cell-like phenotype
and diminish tumor growth of HCC by PPAR-𝛾 agonists,
suggesting their protective role in the context of cancer.
4. Immune Suppression: A Potential Linkage
of Oxidative Stress and Inflammation
4.1. Immune Suppressive Cells to Resolve Inflammation. As
aforementioned, hepatic inflammation has dual roles; they
are essential to maintain tissue healthy and act as critical
drivers of the liver pathologywhen persisted or out of control.
Therefore, resolving inflammation appropriately and timely
is of great significance to maintain liver homeostasis. In this
regard, several basic mechanisms in resolution of inflamma-
tion were proposed. First, soluble anti-inflammatory media-
tors are released in order to fight against the innate immune
response [39]. The second mechanism mainly involves the
activation and induction of immune suppressive cells like
regulatory T cells (Tregs). Additionally, the loss of cell-
cell mediated costimulation on lymphocytes or antigen pre-
senting cells (APC) and the activation of programmed cell
death in those cells are also regarded as potential mecha-
nisms to resolve inflammation. In particular, recently, the
activation and induction of immune suppressive cells in
resolving inflammation have been intensively studied and
attracted great attention [107]. Herein, immune suppressive
cells including Tregs, M2-macrophage, and myeloid-derived
suppressor cells (MDSCs) are particularly discussed with
emphasis on anti-inflammatory effects and linkage to oxida-
tive stress on liver diseases.
4.1.1. Regulatory T Cells. Tregs, a subset of T lymphocytes
that primarily works at sites of inflammation in maintain-
ing peripheral tolerance, have been implicated in several
inflammatory liver diseases. Tregs are equipped with a wide
range of mechanisms of immune suppression, including the
removal of target cells, the regulation of APC, the distur-
bance of metabolic pathways, and the generation of anti-
inflammatory cytokines [108]. Increasing evidences showed
that the reduced frequency and defective function of Tregs
facilitate inflammation in various liver diseases, such as drug
induced liver injury, autoimmune hepatitis, and NASH.
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Accumulating evidence indicates that Tregs are vital
inhibitory mediators of inflammation. It has been demon-
strated that, in the initial phase of acute liver injury, intra-
hepatic Tregs diminished promptly through apoptosis, which
may facilitate inflammation and tissue injury, while in the
healing phase, Tregs are generated through matrix metallo-
proteinase (MMP) cascade-dependent activation of TGF-𝛽
to terminate inflammation [109]. Development fromNAFLD
to NASH is marked by an increased frequency of Th17 cells
in the liver, which is a subset of proinflammatory T helper
cells with the production of IL-17 and is tightly related to
Tregs because the signals for Th17 cells differentiation could
inhibit Tregs. The ratios of Th17/resting Tregs in peripheral
blood and in the liver were also increased [96]. Furthermore,
they inhibit the profibrogenic inflammatory milieu through
suppressing the infiltration of profibrogenic CD8+ and IL-
17+ T cells [110]. In regard of migration of Tregs, it was found
that local proinflammatory cytokines lead to the secretion
of CXCL9 and CXCL10 by sinusoidal and parenchyma cells,
which could recruit CXCR3high circulating Tregs into the
liver. Subsequently, CCR4 guides themigration of these Tregs
within the inflamed liver. These infiltrated Tregs respond to
CCL17 and CCL22 released by activated DCs, thus resulting
in their accumulation in the liver with dendritic cells-
rich inflammatory infiltrates. The reason why inflammation
persists in the presence of Tregs infiltration might be due to
their dysfunctional suppressive effects by programmed death
receptor-1 in the specific microenvironment [111].
Therefore, modulation of Tregs by immune regulatory
agents or adoptive transfer is of great importance in inflamed
liver diseases. For instance, dietary n-3 polyunsaturated fatty
acids (PUFA) protected mice from Con A-induced hepatitis
by enhancing Tregs generation via upregulated expression of
PPAR-𝛾 and TGF-𝛽, which might be a promising potential
therapeutic agent having anti-inflammatory and immunoreg-
ulatory effects for inflammatory diseases [112]. The pop-
ulation of Tregs in the liver significantly decreased after
reperfusion, and adoptive transfer of induced Tregs (iTregs)
that come from TGF-𝛽-induced CD4+CD62L+T cells before
ischemia reperfusion could attenuate liver injury as indicated
by reduced proinflammatory cytokines. In vitro study showed
that iTregs could suppress expression of IL-1𝛽 and TNF-𝛼,
promote transcription of IL-10, and increase phosphorylation
of mothers against decapentaplegic homolog 3 (SMAD3) in
KCs. Furthermore, inhibition of TGF-𝛽 signaling by anti-
TGF-𝛽 abolished the effects on KCs [113]. In acetaminophen-
(APAP-) induced liver injury, the depletion of Tregs ampli-
fied proinflammatory cytokines and aggravated liver injury,
while adoptive transfer of Treg cells showed protective effect
[114].
However, Tregs have also been proposed as foe in several
types of liver diseases such as vital hepatitis and HCC, in
which persisted immune responses are expected to elimi-
nate exogenous infection and neoplasm [115–118]. Failure in
immune regulation by Tregs leads to viral persistence and
tumor growth. Therefore, appropriate strategy in regulating
population and function of Tregs particularly in liver diseases
should be highlighted according to different conditions.
4.1.2. Alternatively Activated (M2) Macrophage. There are
two major phenotypes of macrophages: classically activated
(M1) subset with prototypic macrophage functions which
acts as proinflammatory mediator and an alternatively acti-
vated (M2) subset involved in wound healing with anti-
inflammatory ability. Therefore, macrophage polarization
plays a critical role in inflamed liver diseases [119]. In patients
with minimal liver damage and steatosis, there is higher hep-
atic expression of M2 genes compared to patients with more
severe liver lesions. A complicated interplay between M1
and M2 types of macrophages expressing a wide range of
molecules and receptors is involved in many liver diseases
[120].
In ALD, both activated M1 and M2 macrophages are
present in the liver [121]. The polarization of KCs toward
M1 phenotype initiated the inflammatory process, and it was
indicated that promoting anti-inflammatory M2 phenotype
polarization protects liver fromalcoholic-induced liver injury
through mechanism that relies on apoptotic effects of M2
subset towards their M1 counterparts [121]. In addition, M2
macrophages could trigger hepatocyte senescence mediated
by IL-6 and enhance alcohol-induced hepatocyte senescence
by oxidative stress, which exhibit functional resistance to
apoptosis, thus leading to an early protective effect against
ALD [122]. In mice with chronic alcohol treatment, genes
related with M1 phenotype such as TNF-𝛼, MCP1, and
IL-1𝛽 and genes associated with M2 macrophages such
as Arg1, Mrc1, and IL-10 as well as the population of
CD206(+)CD163(+) M2 macrophages were improved in
the liver. Alcohol could promote M2 phenotype and the
expression of Kru¨ppel-like factor 4 (KLF4), a regulator of
macrophage polarization, whereas the intermediate metabo-
lite of alcohol, acetaldehyde, decreased KLF4 and promoted
M1 macrophage, which may justify the increased M1 and
M2 macrophages in ALD [123]. M2 macrophages expressing
CD163 in liver sinusoids of ALD are abundant; IRF-4, which
is related to IL-4 production, and M2 polarization were also
observed in AH, suggesting thatM2 phenotype plays a role in
AH pathogenesis [120]. In TAA-induced liver injury model,
the double labeling of CD68(+) and CD163(+) macrophages
was found, which indicated thatmacrophage immunopheno-
types are interchangeable in injured sites [124].
Pharmacologic interventions targeting M2 polarization
during the early stages of liver disease may signify a striking
strategy to alleviate liver injury [125, 126]. IL-6, a pleiotropic
interleukin that commonly associated with proinflammatory
effect, is also necessary for inflammation resolution because
of its role in promoting polarization of M2macrophage [119].
Despite the fact that it is associated with the perpetuation and
development of inflammatory disease, the potential benefit
of IL-6 in polarization of M2 macrophage should also be
considered [119].
4.1.3. Myeloid Derived Suppressor Cells (MDSCs). The mye-
loid-derived suppressor cells (MDSCs) are a heterogeneous
population from bonemarrowwith remarkable immunosup-
pressive properties. In the context of tumor setting, MDSCs
help tumor cells escape from immunosurveillance, thereby
endorsing tumor growth [127]. Both innate immune and
10 Oxidative Medicine and Cellular Longevity
adaptive immune responses could be suppressed by MDSC
via several mechanisms including production of large
amounts of nitric oxide (NO) as well as ROS and arginine
depletion. However, their functional significance in the im-
mune system has been appreciated in recent years [128–131].
Under most of the inflammation conditions, MDSCs
infiltrate into the liver and play a protective role in hepatitis
models. In models of acute hepatitis mediated by Con A
and 𝛼-GalCer, farnesoid X receptor (FXR) activation drives
the accumulation of MDSCs to liver via upregulation of
S100A8 and augments the suppressive function of MDSCs
through upregulation of receptor paired immunoglobulin-
like receptor B (PIR-B) by binding the PIR-B promoter [132].
MDSCs function as an important negative feedback loop
and reduction in this cell population facilitates inflammatory
hepatic damage [133]. In the context of immune-mediated
hepatic injury, mTOR negatively regulates the recruitment
of MDSC, which is critically required for protection against
hepatic injury.The inhibition ofmTORby rapamycin or other
inhibitor treatments promotes the expansion of MDSCs that
protect liver from persistent inflammation [134, 135].
Intervention targeting the expansion and activation of
MDSCs is a potential therapeutic approach because deficient
or unsuitable activity of this cell population may contribute
to the pathogenesis of inflammatory liver. It was proposed
that expansion of MDSC could be divided into two processes
regulated by different signal transduction pathways. The first
process is the expansion induced by various cytokines and
growth factors produced in response to chronic stimulation,
which involves factors like IL-6 and VEGF, and signaling
pathways such as STAT3 and NF-𝜅B, which prevents matu-
ration of myeloid cells. Then, a second activating signal pro-
vided by proinflammatorymolecules to drive upregulation of
arginase and iNOS and production of immune suppressive
cytokines is required for their activation [130, 131]. In addition
to above proposed pathways, it is reported that activated
human HSCs during chronic inflammation induced mature
peripheral blood monocytes into MDSCs, and, subsequently,
excessive liver injury might be prevented by local induction
of MDSCs. However, of note, in liver cancer patients, the
expansion of HSC-induced MDSCs plays an opposite role
to facilitate tumor growth by immune suppression [130, 131,
136].
4.2. Oxidative Stress Mediating Failure of Immune Suppression
Response to Promote Inflammation. After unraveling the role
of immune suppression in mediating inflammatory liver dis-
eases, the question that whether oxidative stress, the essential
partner of inflammation, participates in this process has been
put forward. As oxidative stress and inflammation tightly
interplay and drive coherently the progression of liver disease
together, it is reasonable to propose that oxidative stress plays
a critical role to promote inflammation in terms of negatively
regulating the immune suppression. That is, downregulated
immune suppression might be another potential linkage
between oxidative stress and inflammation. As a matter of
fact, increasing evidence demonstrated that oxidative stress
could mediate the dysfunction of immune suppression, thus
leading to the failure of inflammation resolving.
In a study of high-fat fedmicemodel, it was indicated that
the increased oxidative stress in a fatty liver caused the apop-
tosis of Tregs and reduces the population of hepatic Tregs,
resulting in lowered suppression of inflammatory responses.
The treatment with an antioxidantMn(III)tetrakis(4-benzoic
acid)porphyrin chloride decreased the apoptosis of Tregs,
increased the number of hepatic Tregs, and thus improved
hepatic inflammation in mice with NAFLD. This scenario
might be one of the underlying mechanisms that enable
the conversion of simple steatosis into steatohepatitis [137].
In another study, it was indicated that monocytic MDSCs
are induced by catalase-mediated exhaustion of hydrogen
peroxide from mature CD14+ monocytes, and the frequency
of MDSC inversely correlated with hydrogen peroxide level.
The oxidative stress in many liver diseases with decreased
activity of catalase and increased hydrogen peroxide might
inhibit the expansion and activation of hepatic MDSCs that
are expected to resolve overimmune response [138]. There-
fore, oxidative stress might serve as a mediator of impeding
immune suppression response to promote inflammation.
This mechanism also probably explains the potential benefit
of oxidative stress in tumor microenvironment. Therapy of
antioxidant that activates immune suppression to resolve
inflammation might be promising for treatment of various
inflamed liver diseases.
5. Potential Therapeutic Approach on
Liver Diseases
Resolving the vicious cycle between inflammation and oxida-
tive stress is of great clinical importance to treatmany chronic
diseases. It was proposed that identification of primary
abnormality is important to break this cycle. That is, in
the case where oxidative stress presents as primary event,
antioxidants rather than anti-inflammatory agents would be
effective therapeutic strategy [7]. Conversely, if inflamma-
tion appears as the primary abnormality, anti-inflammation
should be considered as a primary therapeutic target. It seems
to be a key factor to explain the puzzling phenomenon of
medical science, where, in certain case of oxidative stress-
related disease, antioxidant treatment showed unsatisfactory
outcome [7, 12]. However, despite promising potential for
clinic practice, unraveling the primary abnormality is difficult
as once the process has been initiated, both inflammation
and oxidative stress show up to promote each other and to
cause progressive injury. With regard to liver diseases, few
researches were dedicated to study the causation of oxidative
stress and inflammation in specific disease settings. There-
fore, application of agents that modulate both oxidative stress
and inflammation is still regarded as the mainstream choice
for the prevention and treatment of liver diseases.
Many medicinal herbs show striking abilities in pro-
tecting the liver due to their remarkable anti-inflammatory
and antioxidative effects. In recent years, traditional Chinese
medicine (TCM)has received broad attention from the public
due to its long-lasting curative effects andmild complications
in treating a variety of liver diseases [178].The applications of
TCM in liver diseases have been systematically reviewed in
our previous papers [2, 8]. In Table 1, agents including herbal
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Table 1: Herbal medicines or derived compounds targeting oxidative stress and inflammation in various liver diseases.
Materials Models Effects Mechanisms Refs.
Phyllanthin CCl4-induced hepatictoxicity
↓ oxidative stress and
hepatic fibrosis
↓ TNF-𝛼/NF-𝜅B and profibrotic
factor TGF-1 mediating
inflammatory signaling
[139]
Gomisin A CCl4-induced acute liverinjury in rats
↓ oxidative stress and
inflammatory response; ↓
fibrogenesis
↓ NF-𝜅B and proinflammatory
mediators [140]
Dillenia suffruticosa
leaves
CCl4-induced hepatic
damage in rats Impedes hepatic damage
↓ oxidative stress and
inflammatory markers [141]
Diallyl disulfide CCl4-induced liver damagein rats
↑ phase II/antioxidant
enzymes; ↓ inflammatory
mediators
↑ Nrf2 pathway; ↓ NF-𝜅B
activation [142]
Folic acid and melatonin CCl4-induced liver injuryin rats
↑ liver function; ↓oxidative
stress and inflammation in
rats
Restore the oxidative stability
and lipid profile; ↓ inflammatory
cytokines and cell survival Akt1
signals
[143]
Ursolic acid CCl4-induced liver injuryin mouse
Inhibiting oxidative stress
and inflammation
↓ JNK, p38 MAPK, ERK, and
NF-𝜅B [144]
Aloin Chronic alcoholic liverinjury in mice
↓ chronic alcoholic liver
injury
↓ lipid accumulation, oxidative
stress, and inflammation [145]
Wild bitter gourd Chronic alcohol-inducedliver injury in mice
↓ oxidative stress and
inflammatory responses
↑ antioxidant defence system; ↓
MDA and proinflammatory
cytokines; ↓ CYP2E1, SREBP-1,
FAS, and ACC protein expression
[146]
Lutein Alcohol-induced liverinjury in rats
↓ oxidative stress and
inflammation
↓ inflammatory proteins and
cytokines; ↑ Nrf2 levels; ↑
antioxidant enzymes
[147]
Fucoidan High-fat diet-inducedNAFLD in rats
↓ steatohepatitis and
insulin resistance
↓ oxidative stress and
inflammatory cytokines [148]
Epigallocatechin gallate
High-fat diet-induced
nonalcoholic fatty liver
disease in rats
↓ fibrosis, oxidative stress,
and inflammation
Modulating the activities of
TGF/SMAD, PI3 K/Akt/FOXO1,
and NF-𝜅B
[149]
Magnolia extract High-fat diet-induced liverdamage in mice ↓ fibrosis in the liver
Inhibition of lipid accumulation,
inflammation, and oxidative
stress
[150]
Brown alga Ecklonia
cava polyphenol extract
High-fat diet-induced
obese mice
↓ hepatic lipogenesis,
oxidative stress, and
inflammation
↑ AMPK and SIRT1 [151]
Chicoric acid High-fat diet-fed mice
↓ hepatic steatosis,
inflammation, and
oxidative stress
↑ antioxidant defense system; ↑
adipocytokines and
adipogenesis-associated proteins
[152]
Ghrelin High-fat diet-inducedNAFLD in rats
↓ inflammation, oxidative
stress, and apoptosis
Restoration of LKB1/AMPK and
PI3 K/Akt pathways [153]
Curcumin, silybin
phytosome, and R-lipoic
acid
TAA-induced chronic
hepatitis in rat model
↓MDA, GSH depletion,
and collagen deposition
↓macrophage activation, NF-𝜅B,
TNF-𝛼, and IL6 [154]
Carvacrol TAA-induced liver injuryin rats
Abrogation of oxidative
stress, inflammation, and
apoptosis
↓ NF-𝜅B [155]
Fermented rooibos
extract
LPS-induced liver injury in
rats Attenuated liver injury
↓ oxidative stress and
proinflammatory cytokines [156]
𝛼-Lipoic acid LPS-induced liver injury
Antioxidant,
anti-inflammatory, and
antiapoptotic activities
↓ iNOS, COX-2, TNF-𝛼, NF-𝜅B,
IL-1𝛽, and IL-6 [157]
Paeoniflorin
A mouse model of hepatic
ischemia/reperfusion
injury
↓ hepatic
ischemia/reperfusion
injury
Via antioxidative,
anti-inflammatory, and
antiapoptotic pathways
[158]
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Table 1: Continued.
Materials Models Effects Mechanisms Refs.
Agaricoglycerides
Hepatic
ischemia/reperfusion
injury in mouse
Protect against hepatic
injury
↓ inflammatory response,
oxidative stress, and expression
of NF-𝜅B
[159]
Cannabidiol
Hepatic
ischemia/reperfusion
injury in mouse
↓ oxidative stress and
inflammation and cell
death
↓ key inflammatory pathways,
independent of classical CB1/2
receptors
[160]
Dioscin
Hepatic
ischemia/reperfusion
injury in rats
Inhibition of
oxidative-nitrative stress,
inflammation, and
apoptosis
↓ IL-1A, IL-6, TNF-𝛼,
intercellular adhesion
molecule-1, MIP-1𝛼, MIP-2, Fas,
and FasL; ↓NF-𝜅B, AP-1, COX-2;
↓ JNK, ERK, and p38 MAPKs
phosphorylation; ↑ Bcl-2 and
Bcl-x
[161]
Delta(8)-
tetrahydrocannabivarin
Hepatic
ischemia/reperfusion
injury in mice
Prevents hepatic injury and
inflammation Cannabinoid CB2 receptors [162]
Green tea extract
Hepatic injury after
hemorrhage/resuscitation
in rats
↓ apoptosis, oxidative
stress, and inflammation ↓ JNK and NF-𝜅B [163]
Astaxanthin and Corni
fructus
Streptozotocin-induced
diabetic rats
↓ glucose concentration; ↓
ROS and lipid peroxidation
↓ advanced glycation end
product formation and
anti-inflammation
[164]
Resveratrol Streptozotocin-inducedtype 1 diabetic rats
↓ oxidative stress and
inflammation ↑Mn-SOD; ↓ NF-𝜅B and IL-1𝛽; [165]
𝛼-Lipoic acid Aflatoxin B-1-induced liverdamage in broilers
↓ oxidative damage and
inflammatory responses
↓ hepatic proinflammatory
cytokines; ↓ NF-𝜅B [166]
Niacin
HepG2 or human primary
hepatocytes stimulated
with palmitic acid
↓ fat accumulation,
oxidative stress, and
inflammatory cytokine IL-8
↓ hepatocyte DGAT2 and
NADPH oxidase activity [167]
Quercetin
Tripterygium
glycosides-induced acute
liver injury in mice
↓ liver injury ↓ oxidative stress andinflammation [168]
Troxerutin
2,2󸀠,4,4󸀠-
Tetrabromodiphenyl
ether-induced liver
inflammation in mouse
↓ liver inflammation ↓ oxidative stress-mediatedNAD+-depletion [169]
Geraniol
2-Acetylaminofluorene-
induced liver injury in
rats
↓ oxidative stress,
inflammation, and
apoptosis
↓ caspase-3 and caspase-9,
COX-2, NF-𝜅B, PCNA, iNOS,
VEGF, and disintegration of
DNA
[170]
Thymoquinone and
curcumin
Gentamicin-induced liver
injury in rats
↓ deleterious effects on liver
function and histological
integrity
↑ antioxidant defense system; ↓
inflammation and apoptosis [171]
Chrysin Cisplatin-induced hepaticdamage in rats ↓ hepatotoxicity
↓ oxidative stress and
inflammatory response [172]
Bazhen Decoction Acetaminophen-inducedacute liver injury in mice
↓ ALT, AST, ALP, LDH,
TNF-𝛼, IL-1𝛽, ROS,
TBARS, GSH depletion,
and loss of MMP
↑ SOD, CAT, GR, and GPx; ↓
inflammatory mediators; ↓
Bax/Bcl-2 ratio and caspase-3,
caspase-8, and caspase-9
[173]
Probiotic Lactobacillus
casei Zhang
Endotoxin- and
D-galactosamine-induced
liver injury in rats
Antioxidative and
anti-inflammatory effects TLR4 signaling [174]
Lutein Guinea pigs fed ahypercholesterolemic diet
↓ oxidative stress and
inflammation ↓ NF-𝜅B DNA binding activity [175]
Galangin Fructose-induced liverdamage in rat ↓ oxidative damage ↓ inflammatory pathway [176]
Ganoderma applanatum
terpenes
Benzo(alpha)pyrene-
induced liver damage in
mouse
Decreased oxidative stress
and inflammation
↑ antioxidant enzymes and
suppressing inflammatory
response
[177]
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medicine and derived compounds targeting oxidative stress
and inflammation in various liver diseases were summarized.
Particular emphasis herein is put upon several pure com-
pounds from herbal plants with strong anti-inflammatory
and antioxidative ability. Furthermore, severalmedicines that
prevent liver disease by mechanism of regulating immune
suppression response, antioxidant, and anti-inflammation
were reviewed.
Berberine (BBR), an alkaloid isolated from Coptidis Rhi-
zoma, has been reported with several pharmacological activ-
ities including antitumoral, antimicrobial, glucose- and cho-
lesterol-lowering, and immunomodulatory properties by us
and others [179–181]. Importantly, it exhibited antisteatotic,
anti-inflammatory, and antioxidative effect via regulating
AMPK and low-density lipoprotein receptor expression by
ERK and JNK pathways [8]. BBR treatment significantly
attenuated hepatic inflammation, lipid peroxides, and fibrosis
in NAFLD model, which may be a therapeutic strategy to
prevent the progress of hepatic steatosis to NASH [182]. In
another study, it was shown that daily administration of BBR
at the dose of 50mg/kg for three weeks relieved oxidative
stress, inflammation, hyperglycemia, hyperlipidemia, hyper-
insulinemia, and the neurotoxicity related with NASH [183].
Pseudoberberine, a berberine analogue, displayed antioxi-
dant and anti-inflammatory activities in diabetic mice with
fatty liver. Due to poor bioavailability of BBR via oral admin-
istration, pseudoberberinemight be a new oral hypoglycemic
agent for NAFLD [184]. It has been reported that BBR ame-
liorated the liver fibrosis in mice with CCl4 administration
in a dose- and time-dependent manner. The underlying
mechanism of its protective effect on chronic liver fibrosis
might be due to reduced oxidative stress, inhibition of TNF-
𝛼, COX-2, and iNOS expression, and activation of AMPK
pathway [185, 186]. The effect of BBR on the drug isoniazid-
induced hepatotoxicity has been conducted. The results
showed that BBR protected liver from injury through upregu-
lation of PPAR-𝛾 and subsequently suppression of NF-𝜅B and
iNOS and release of the proinflammatory cytokines [187]. In
addition to isoniazid, BBR also alleviates cyclophosphamide-
induced hepatotoxicity by modulating antioxidant defense
and inflammatory mediators [188].
Curcumin, a polyphenolic antioxidative constituent in
many plants, turmeric in particular, showed remarkable
hepatoprotective effects. In a rat model with CCl4-caused
liver injury, curcumin could effectively protect liver from
fibrosis. The results showed that curcumin attenuates oxida-
tive stress by upregulating hepatic glutathione level, lead-
ing to the reduction of lipid hydroperoxide. Additionally,
curcumin intensely suppresses inflammation by diminish-
ing contents of inflammatory cytokines, including IFN-
𝛾, TNF-𝛼, and IL-6. Furthermore, curcumin inhibits HSC
activation by increasing the level of PPAR-𝛾 and reducing
platelet-derived growth factor and TGF-𝛽 as well as their
receptors and type I collagen [189]. In rat model with
thioacetamide- (TAA-) induced chronic hepatitis, hepatic
levels of MDA, collagen deposition, inflammatorymediators,
and liver function were improved by curcumin treatment
[154]. The effect of curcumin on a drug gentamicin-induced
liver injury was evaluated in a study. The results showed that
liver function indicated as aspartate aminotransferase (AST),
alanine transaminase (ALT), and lactate dehydrogenase
(LDH) activities, liver histological alterations, antioxidant
defense, inflammatory mediators like TNF-𝛼 level, proapop-
totic proteins caspase 3 and Bax expression were signifi-
cantly improved by curcumin [171]. Curcumin also displayed
protective effects on tetrachloro-p-benzoquinone- (TCBQ-)
induced hepatotoxicity in mice, which was demonstrated by
the improved AST and ALT activities, and histopathological
changes including centrilobular necrosis and inflammatory
cells infiltration. The elevated TBAR level and the inhibited
activities of SOD and catalase and upregulated iNOS, COX-
2, IL-1𝛽, IL-6, TNF-𝛼, and NF-𝜅B induced by TCBQ were
effectively reduced by curcumin through the activation of
Nrf2 signaling [190].
Epigallocatechin gallate (EGCG) is a type of catechin in
many natural plants such as green tea. As a polyphenol, it has
a wide range of health benefits. For instance, EGCG could
significantly relieve bile duct ligation-induced hepatic dam-
age in mice via improving mitochondrial oxidative stress and
inflammation. EGCG reduced gene expression of profibrotic
markers like collagen, fibronectin, 𝛼-SMA, and connective
tissue growth factor (CTGF), cell death marker like DNA
fragmentation and PARP activity, mitochondrial oxidative
stress, NF-𝜅B activity, and proinflammatory cytokines such
as TNF-𝛼, MIP1-𝛼, IL-1𝛽, and MIP2 in bile duct ligation
mice. Mitochondrial electron transport chain complexes
and antioxidant defense enzymes like GSH-Px and SOD
were improved by EGCG administration [191]. In NAFLD
model, treatment with EGCG improved fatty score, necrosis,
and inflammatory foci, restored liver function, and reduced
fibrogenesis with downregulation of nitrotyrosine formation
and proinflammatory markers such as iNOS, COX-2, and
TNF-𝛼. The activity of TGF/SMAD, PI3K/Akt/FOXO1, and
NF-𝜅B pathways could be counteracted by EGCG, suggest-
ing that EGCG is beneficial in the prevention of NAFLD
[149]. In addition, EGCG effectively weakened the severity
of CCl4-induced liver injury and the progression of liver
fibrosis by mechanism of the reduction in oxidative stress
and the inflammatory response [192]. Furthermore, it was
demonstrated that, even in healthy rats, EGCG extends
lifespan by reducing liver function damage and attenuating
age-associated inflammation and oxidative stress. EGCG
inhibited NF-𝜅B signaling and increased the expressions of
longevity factors including silent mating type information
regulation 2 homolog 1 (SIRT1) and forkhead box class O 3a
(FOXO3a) [193].
Lipoic acid (LA) is an organosulfur compound derived
from octanoic acid, which has two sulfur atoms connected by
a disulfide bond and thus can be oxidized, and the molecule
presents as two enantiomers (S)-(−)-lipoic acid (SLA) and
(R)-(+)-lipoic acid (RLA) and as a racemic mixture (R/S)-
lipoic acid (R/S-LA). Its effect on many liver diseases has
been widely studied. LA protects liver from aflatoxin B-
1 induced injury via downregulating mRNA level of IL-6
and decreasing the protein expressions of both NF-kB p65
and iNOS in broilers [166]. In liver injury induced by LPS,
a key inflammatory component of Gram-negative bacteria
which contributes to the development of hepatic failure,
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administration of LA following LPS treatment effectively
prevented oxidative stress and hepatic inflammation [194].
In another study, the protective role of LA in LPS/D-gal-
actosamine- (D-GalN-) induced fulminant hepatic failure
in mice was studied. It was found that ROS and TBARS
were eliminated, while activity of hepatic CAT and GPx was
increased by LA treatment. Additionally, pretreatment with
LA significantly decreased LPS/D-GalN-induced expression
of inflammatory mediators such as TNF-𝛼, NF-𝜅B, iNOS,
COX-2, IL-6, and IL-1𝛽 [157]. In ratmodel with TAA-induced
chronic hepatitis, hepatic levels of MDA and liver function
were improved by RLA treatment. The depletion of GSH,
macrophage activation, collagen deposition, and expression
of NF-𝜅B, TNF-𝛼, and IL-6 were significantly decreased in
response to RLA administration [154]. In addition, it was
found that R/S-LA coadministration could effectively disrupt
a vicious pathogenic circle constituting oxidative stress,
insulin resistance, and inflammation induced by fructose in
rats model [195].
6. Conclusion
The critical roles of oxidative stress and inflammation in-
volved in the pathogenesis of liver diseases have been high-
lighted for decades, and accumulating evidence showed that
a vicious cycle could be created by oxidative stress and
inflammation, which participates tightly in the progression
of liver diseases. Oxidative stress could elevate proinflam-
matory gene expression by signaling pathways such as NF-
𝜅B, while infiltrated inflammatory cells and cytokines like
IL-6 and IFN-𝛾 could produce more oxidative stress. Their
tight interactions make the hepatic pathological process
complicated. More key interplayed molecules and targets are
expected to be discovered in future studies. Importantly, as
immune suppressive cells including Tregs, M2 macrophage,
andMDSCs are of great importance to resolve inflammation,
the failure of immune suppression leads to the sustained
inflammation. Increasing evidence showed that immune
suppression might be a link between oxidative stress and
inflammation as indicated by the increased oxidative stress
mediating inhibition of immune suppression in inflamed
liver. Intervention mediating immune suppression might
be promising to alleviate both inflammation and oxidative
stress. Application of agents modulating both oxidative stress
and inflammation is still considered to be mainstream choice
for the prevention and treatment of liver diseases. Many
medicinal herbs or derived compounds show striking abil-
ities in protecting the liver due to their remarkable anti-
inflammatory and antioxidative effects in animal studies. In
future study, the related translational research should also be
further conducted and improved to realize the application of
these agents in treating and prevention of liver diseases. Fac-
tors such as the duration of treatment, dosage, bioavailability
in human body,mode of administration, and rigorous clinical
study design are needed to be considered. In short, intensive
efforts should be made to address the vicious pathological
cycle forming by oxidative stress and inflammation through
interacted pathways or immune suppression.
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